Search Results - "Chirgwin, J. H."

The impact and indications for Oncotype DX on adjuvant treatment recommendations when third‐party funding is unavailable by Chin‐Lenn, L., Boer, R. H., Segelov, E., Marx, G. M., Hughes, T. M., McCarthy, N. J., White, S. C., Foo, S. S., Rutovitz, J. J., Della‐Fiorentina, S., Jennens, R., Antill, Y. C., Tsoi, D., Cronk, M. F., Lombard, J. M., Kiely, B. E., Chirgwin, J. H., Gorelik, A., Mann, G. B.

“…Objectives Industry‐supported decision impact studies demonstrate that Oncotype Dx (ODX) changes treatment recommendations (TR) in 24–40% of hormone…”
Get full text

Menopause surveillance recommendations for patients with endocrine responsive breast cancer by Chirgwin, JH, Lewis, J, Woodfield, R, Davis, SR, Eden, J, deBoer, R

“…Abstract #1148 Background: Women aged under 55 receiving breast cancer treatment frequently experience temporary or permanent menopause as a result. Although…”
Get full text